A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis

Stopped After an extensive review,the ASPIRE in CKD study was terminated because it was not possible to complete the study in an appropriate time frame.

Conditions

• Chronic Kidney Disease
• Hyperphosphatemia

Interventions

• DRUG: Sevelamer carbonate
• DRUG: Placebo for sevelamer carbonate

Sponsor

Genzyme, a Sanofi Company